Renling Yao1,2, Li Zhu3, Jian Wang2, Jiacheng Liu4, Ruifei Xue1, Leyang Xue5, Longgen Liu6, Chunyang Li7, Haiyan Zhao8, Juan Cheng9, Songping Huang10, Yang Li11, Xiang-An Zhao12, Chuanwu Zhu3, Ming Li13, Rui Huang2, Chao Wu1,2,4. 1. Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. 2. Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. 3. Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China. 4. Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. 5. Department of Critical Medicine, Huai'an No. 4 People's Hospital, Huai'an, China. 6. Department of Infectious Diseases, The Third People's Hospital of Changzhou, Changzhou, China. 7. Department of Infectious Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. 8. Department of Infectious Diseases, The People's Hospital of Suqian, Suqian, China. 9. Department of Infectious Diseases, Yancheng Second People's Hospital, Yancheng, China. 10. Department of Infectious Diseases, Nantong Third People's Hospital, Nantong University, Nantong, China. 11. Department of Infectious Diseases, Taizhou People's Hospital, Taizhou, China. 12. Department of Gastroenterology, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China. 13. Department of Hepatology, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Abstract
BACKGROUND: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID-19 patients with non-alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)-determined liver fibrosis with clinical outcomes of COVID-19 patients with NAFLD. METHODS: The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis. RESULTS: A total of 86 COVID-19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty-eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202-56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193-102.439, p = 0.034) were independent risk factors of severe illness in COVID-19 patients with NAFLD. CONCLUSION: NAFLD patients with NFS-determined advanced liver fibrosis are at higher risk of severe COVID-19.
BACKGROUND: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID-19patients with non-alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)-determined liver fibrosis with clinical outcomes of COVID-19patients with NAFLD. METHODS: The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis. RESULTS: A total of 86 COVID-19patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty-eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202-56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193-102.439, p = 0.034) were independent risk factors of severe illness in COVID-19patients with NAFLD. CONCLUSION: NAFLD patients with NFS-determined advanced liver fibrosis are at higher risk of severe COVID-19.